Crystalline forms of N[4[4-(4-Morpholinyl)-7H-Pyrrolo[2-3-D]Pyrimidin-6-yl]Phenyl]-4-[[3(R)-[(1-Oxo-2-Protein-1-yl)Amino]-1-Piperidinyl]Methyl]2-Pyridinecarboxamide]
Satish Goud Puppali, Sunnyvale, CA (US); James T. Palmer, Warrandyte (AU); Thorsten A. Kirschberg, San Carlos, CA (US); Angelina Sau Man Wong, Redwood City, CA (US); Heow Meng Tan, Redwood City, CA (US); Jay Li, Redwood City, CA (US); Jing Lin, Redwood City, CA (US); Ming Gao, Shanghai (CN); Junlu Ding, Shanghai (CN); Shuang Li, Shanghai (CN); Yuyao Gu, Shanghai (CN); Hongyan He, Shanghai (CN); Bo Zheng, Shanghai (CN); Yanjing Zhou, Shanghai (CN); and Mei You, Shanghai (CN)
Assigned to Biomea Fusion, Inc., Redwood City, CA (US)
Filed by BIOMEA FUSION, INC., Redwood City, CA (US)
Filed on Jan. 30, 2024, as Appl. No. 18/427,226.
Application 18/427,226 is a continuation of application No. PCT/US2024/011848, filed on Jan. 17, 2024.
Claims priority of provisional application 63/480,443, filed on Jan. 18, 2023.
Claims priority of provisional application 63/483,648, filed on Feb. 7, 2023.
Claims priority of provisional application 63/486,405, filed on Feb. 22, 2023.
Claims priority of provisional application 63/492,404, filed on Mar. 27, 2023.
Claims priority of provisional application 63/579,754, filed on Aug. 30, 2023.
Prior Publication US 2024/0300950 A1, Sep. 12, 2024
1. A crystalline Form K of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide (Compound A) of formula (I):
wherein the crystalline Form K is characterized by an X-ray powder diffraction pattern comprising at least two characteristic peaks at angles (° 2θ) selected from the group consisting of 10.483°±0.2° 2θ, 12.756°±0.2° 2θ, and 19.071°±0.2° 2θ.
